(Reuters) -Drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Thursday, boosted by cost-cutting, a ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Pfizer has taken a $1.2 billion hit after reassessing the prospects of two antibody-drug conjugates (ADC) it picked up in the ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...

Stocks are struggling for direction today, and one sector that represents this choppiness is blue-chip drugmakers. Merck & Co ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Investors have been cool to Pfizer, with shares down some 50% since record highs in 2021. Pfizer Chief Executive Albert Bourla has been looking to turn around the company's performance, taking steps ...

U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...